270 related articles for article (PubMed ID: 32779394)
21. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
22. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
[TBL] [Abstract][Full Text] [Related]
23. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
24. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
[TBL] [Abstract][Full Text] [Related]
25. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
26. The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Li J; Xiang C; Wang Y; Zhou Y; Cao S; Ling X; Ye J; Zheng J; Shao L; Zhong H; Han Y
Ann Transl Med; 2021 May; 9(9):779. PubMed ID: 34268392
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Camelliti S; Le Noci V; Bianchi F; Moscheni C; Arnaboldi F; Gagliano N; Balsari A; Garassino MC; Tagliabue E; Sfondrini L; Sommariva M
J Exp Clin Cancer Res; 2020 Nov; 39(1):236. PubMed ID: 33168050
[TBL] [Abstract][Full Text] [Related]
29. Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
Zhang D; Zhang Y; Huang Y; Kong L; Yu J
Lung Cancer; 2020 Jan; 139():18-21. PubMed ID: 31704279
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
[TBL] [Abstract][Full Text] [Related]
31. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
32. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
33. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
34. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
35. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
36. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
37. Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis.
Asano Y; Yamamoto N; Demura S; Hayashi K; Takeuchi A; Kato S; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Sone T; Okuda M; Matsumoto I; Yano S; Tsuchiya H
Cancer Med; 2023 Jun; 12(11):12425-12437. PubMed ID: 37076988
[TBL] [Abstract][Full Text] [Related]
38. Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.
Takeuchi E; Kondo K; Okano Y; Kunishige M; Kondo Y; Kadota N; Machida H; Hatakeyama N; Naruse K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3139-3147. PubMed ID: 35871700
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
40. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]